PRESS RELEASE published on 07/15/2025 at 14:00, 1 year ago Eckert & Ziegler: Outstanding Training Quality Once Again Awarded Eckert & Ziegler SE awarded for exceptional training quality by Berlin Chamber of Industry and Commerce for the fourth consecutive time, emphasizing practical experience and career prospects for trainees Eckert & Ziegler Career Prospects Training Quality Berlin Chamber Of Industry And Commerce Trainee Team
BRIEF published on 06/18/2025 at 16:10, 1 year 1 month ago Eckert & Ziegler SE Declares EUR 0.50 Dividend at Annual General Meeting Annual General Meeting Shareholders Dividend Financial Year 2024 Eckert & Ziegler SE
BRIEF published on 06/18/2025 at 16:10, 1 year 1 month ago Eckert & Ziegler SE déclare un dividende de 0,50 € lors de son assemblée générale annuelle Actionnaires Dividende Assemblée Générale Annuelle Eckert & Ziegler SE Exercice Financier 2024
PRESS RELEASE published on 06/18/2025 at 16:05, 1 year 1 month ago Annual General Meeting of Eckert & Ziegler SE Approves Dividend of EUR 0.50 Eckert & Ziegler SE's Annual General Meeting approves dividend of EUR 0.50 per share for 2024 fiscal year. Detailed voting results available online Annual General Meeting Shareholders Voting Results Dividend Eckert & Ziegler SE
BRIEF published on 06/05/2025 at 10:05, 1 year 2 months ago Eckert & Ziegler se développe avec l'approbation d'Illuccix® en Allemagne Gallium-68 Médecine Nucléaire Cancer De La Prostate Illuccix® Imagerie PSMA-PET
BRIEF published on 06/05/2025 at 10:05, 1 year 2 months ago Eckert & Ziegler Expands with Approval of Illuccix® in Germany Gallium-68 Nuclear Medicine Prostate Cancer Illuccix® PSMA-PET Imaging
PRESS RELEASE published on 06/05/2025 at 10:00, 1 year 2 months ago Eckert & Ziegler: Illuccix® PSMA-PET Imaging Agent Receives Approval in Germany Eckert & Ziegler announces the approval of Illuccix® PSMA-PET Imaging Agent in Germany, expanding its nuclear medicine portfolio and partnership with Telix Pharmaceuticals Eckert & Ziegler Germany Approval Illuccix PSMA-PET
BRIEF published on 05/30/2025 at 10:05, 1 year 2 months ago Eckert & Ziegler Hosts Successful Boston Radionuclide Theranostics Forum Precision Oncology Industry Collaboration Radiopharmaceuticals Theranostics Forum Event Insights
BRIEF published on 05/30/2025 at 10:05, 1 year 2 months ago Eckert & Ziegler organise avec succès le Boston Radionuclide Theranostics Forum Oncologie De Précision Produits Radiopharmaceutiques Collaboration Industrielle Forum Théranostique Informations Sur Les Événements
PRESS RELEASE published on 05/30/2025 at 10:00, 1 year 2 months ago Eckert & Ziegler Organizes Third Boston Radionuclide Theranostics Forum Eckert & Ziegler successfully completes the 3rd annual Boston Radionuclide Theranostics Forum, gathering key leaders to discuss radionuclides in precision oncology Innovation Eckert & Ziegler Precision Oncology Radiopharmaceuticals Boston Radionuclide Theranostics Forum
Published on 08/07/2026 at 23:15, 2 days 8 hours ago Faraday Copper Reports Second Quarter 2026 Financial Results
Published on 08/07/2026 at 23:00, 2 days 8 hours ago Rio Grande Resources Announces up to $2,500,000 Non-Brokered Private Placement Financing
Published on 08/07/2026 at 22:30, 2 days 9 hours ago UraniumX Deploys $3.8 Million to Athabasca Basin Exploration
Published on 08/07/2026 at 22:15, 2 days 9 hours ago Noram Lithium Engages 1353656 BC Ltd. for Marketing and Management Consulting Services
Published on 08/10/2026 at 07:30, 29 minutes ago GEA second quarter figures: Double-digit growth in order intake and revenue, with significantly higher profitability
Published on 08/10/2026 at 07:29, 29 minutes ago EQS-Adhoc: q.beyond accelerates AI transformation and adjusts outlook for 2026 financial year
Published on 08/10/2026 at 07:10, 49 minutes ago Hypoport delivers solid gross profit growth and marked EBIT increase in first half of 2026
Published on 08/10/2026 at 07:00, 59 minutes ago Infracore SA announces partial exercise of the over-allotment option
Published on 08/10/2026 at 07:00, 59 minutes ago BIOPHYTIS ANNOUNCES APPROVAL OF THE OBA CLINICAL TRIAL IN BRAZIL AND SHARES ITS OUTLOOK FOR BIO101 IN OBESITY
Published on 08/10/2026 at 07:00, 59 minutes ago Biophytis annonce l’autorisation de l’étude clinique OBA au Brésil et partage les perspectives de BIO101 dans l’obésité
Published on 08/07/2026 at 18:54, 2 days 13 hours ago Covivio - Déclaration des transactions sur actions propres réalisées du 03 août 2026 au 07 août 2026
Published on 08/07/2026 at 18:54, 2 days 13 hours ago Covivio - Information on Treasury shares transactions between August 3rd, 2026, and August 7th, 2026
Published on 08/07/2026 at 18:40, 2 days 13 hours ago Disclosure of transactions in own shares from August 3 to August 7, 2026
